The AlphaLISA® Human PD-L1 Detection Kit is designed for detection and quantitation of Human PD-L1 (CD274/B7-H1) in immunoassay buffer, human serum, plasma, and cell culture supernatants using a homogeneous AlphaLISA assay (no wash steps).
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
|Part Number||Unit Size||List Price||Your Price||Quantity|
|AL355HV||100 assay points||675.00 USD|
|AL355C||500 assay points||1433.00 USD|
|AL355F||5,000 assay points||9500.00 USD|
You successfully added item(s) to your cart
Programmed death ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7 homolog1 (B7-H1) belongs to the growing B7 family of immune proteins and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. Human PD-L1 is constitutively expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. PD-L1, together with PD-L2, are two ligands for PD-1 (programmed death 1), a member of the CD28 family of immunoreceptors. By binding to PD-1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Disclaimer: For research use only. Not for use in diagnostic procedures.
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||100 assay points|
You have selected:
|Resource Type||File Name||File Format|
|Brochure||Alpha product listing||PDF 124 KB|
|Application Note||Development of an AlphaLISA Assay for Screening Inhibitors of the TIM-3/Gal-9 Interaction||PDF 3 MB|
|Application Note||Measuring PD-L1 Expression in Breast Cancer Cell Lines with AlphaLISA||PDF 4 MB|
|Application Note||Protocol Optimization for Detection and Quantification of Membrane-Bound Proteins Using AlphaLISA Te||PDF 2 MB|
|Application Note||Quantifying Changes in CD28 and CTLA-4 Levels in Peripheral Blood Mononuclear Cells with AlphaLISA||PDF 1 MB|
|Application Note||Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint||PDF 1 MB|
|Technical Note||AlphaLISA Assays for Immune Checkpoint Detection and Quantitation||PDF 532 KB|
|Data Sheet||AlphaLISA human PD-L1 Detection Kit||PDF 507 KB|
|Event||Society of Laboratory Automation & Screening (SLAS)||Event|